A Multicentre, Retrospective Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Nintedanib (Primary) ; Antineoplastics; Protein kinase inhibitors
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 06 Apr 2018 Planned End Date changed from 26 Mar 2018 to 30 Apr 2018.
- 06 Apr 2018 Planned primary completion date changed from 26 Mar 2018 to 30 Apr 2018.
- 12 Mar 2018 Planned End Date changed from 31 Jan 2018 to 26 Mar 2018.